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Abstract
Purpose Patients with advanced disease are living longer and
commonly used patient-reported outcome measures (PROMs)
may miss relevant elements of the quality of extended surviv-
al. This systematic review examines the measures used to
capture aspects of the quality of survival including impact
on patients’ everyday lives such as finances, work and family
roles.
Methods Searches were conducted in MEDLINE, EMBASE,
CINAHL and PsycINFO restricted to English language arti-
cles. Information on study characteristics, instruments and
outcomes was systematically extracted and synthesised. A
predefined set of criteria was used to rate the quality of studies.
Results From 2761 potentially relevant articles, 22 met all
inclusion criteria, including 10 concerning financial distress,
3 on roles and responsibilities and 9 on multiple aspects of
social well-being. Generally, studies were not of high quality;
many lacked bias free participant selection, had confounding
factors and had not accounted for all participants. High levels
of financial distress were reported and were associated with
multiple demographic factors such as age and income. There
were few reports concerned with impacts on patients’ roles/
responsibilities in everyday life although practical and emo-
tional struggles with parenting were identified. Social difficul-
ties were common and associated with multiple factors includ-
ing being a caregiver. Many studies were single time-point
surveys and used non-validated measures. Exceptions were
employment of the COST and Social Difficulties Inventory
(SDI), validated measures of financial and social distress
respectively.
Conclusions Impact on some important parts of patients’ ev-
eryday lives is insufficiently and inconsistently captured.
Further PROM development focussing on roles and responsi-
bilities, including work and caring for dependents, is
warranted.
Implications for Cancer Survivors Factors such as finances,
employment and responsibility for caring for dependants (e.g.
children and elderly relatives) can affect the well-being of
cancer survivors. There is a need to ensure that any instru-
ments used to assess patients’ social well-being are broad
enough to include these areas so that any difficulties arising
can be better understood and appropriately supported.
Keywords Patient-reported outcomes . Cancer . Social
impact . Financial burden . Quality of survival . Quality of life
Introduction
Rapidly emerging novel treatments in oncology, particularly
in advanced disease, mean that more patients are living longer
[1]; for those who cannot be cured, the goal of therapy is
extending survival whilst maintaining or improving quality
of life. This changing landscape has implications for the tools
both researchers and clinicians have at their disposal to eval-
uate and improve patient outcomes holistically.
The measurement of a patient’s subjective experience of
both the symptoms of disease and treatment-related toxicity
within clinical trials has increased [2, 3]. This practice is
expanding to routine care and follow-up [4, 5] with the
concept of health-related quality of life (HRQoL) sub-
sumed under the broader term of patient-reported outcomes
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(PROs). Good, well-validated HRQoL instruments have
been used in oncology for some time, measuring the impact
of disease on functioning and well-being. Many checklists
and subscales are available enabling measurement of treat-
ment related side effects as well as symptoms of disease.
These are usually designed for use with more generic
HRQoL questionnaires revealing the overall impact that
disease and treatment may exert on physical, functional,
emotional and social well-being. The best validated, gener-
ic patient-reported outcome measures (PROMs) used most
frequently are the European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30 [6] and the
Functional Assessment of Cancer Therapy (FACT-G) [7]
questionnaires. Both have disease-specific cancer modules
or subscales, but the FACT has a wider range of treatment-
specific subscales.
Although the more frequent use of PROMs is encouraging,
there may well be areas of concern impacting the quality of
survival that are insufficiently assessed. A previous systematic
review by Muzzati and Annunziata [8] showed that some
PROMs examine different and limited aspects of patients’
social well-being. For example the subscale of the EORTC
QLQ-C30 refers to social and role functioning, the FACT-G
to relatives and relationships and the Psychological Screen for
Cancer [9] to social support. The authors of this previous
systematic review [8] commented that none of the multidi-
mensional HRQoL instruments totally captured the complex-
ity of ‘social impact’. This led them to a systematic search of
instruments dedicated solely to the assessment of the social
aspects of the cancer experience (or validated in cancer pop-
ulations) which yielded 27 articles relating to 14 instruments.
The social dimensions covered by these tools were predomi-
nantly communication (couple/family/caregiver), relation-
ships (with family and friends) and support (from family and
friends) and are a reflection of the search terms derived from
the social items listed in existing HRQoL measures and a
limiting factor of the review. By deriving the search terms
using this method, it is not surprising to have identified tools
that measure similar issues to those of the social domains of
the HRQoL instruments, but potentially covering them in
greater depth. Our contention is that the literature on the social
concerns and issues faced by cancer patients contains a
broader spectrum of social issues than the items on those
existing HRQoL instruments. Though Muzzati and
Annunziata’s review systematically searched for more depth,
it failed to extend its range potentially missing areas of inter-
est. The review did identify one instrument, the Social
Difficulties Inventory [10], which included an ‘everyday liv-
ing’ subscale examining care of dependents, recreation and
independence and a ‘money matters’ subscale with items on
work, finances and welfare benefits. The social problems that
patients with cancer have has been documented for some con-
siderable time with early literature showing that problems can
be experienced with employment [11–13], managing daily
living [12, 14], finances [15, 16] and insurance [13, 17].
Later work has continued to reveal the social issues that cause
significant concern for patients. Both qualitative research
[18–20] and pure economic surveys/evaluations [21–25] illus-
trate that financial worry and hardship are both evident and
prevalent. Furthermore, quantitative reports of return to work
rates and functional abilities in terms of work performance and
obstacles [26–33] and qualitative studies exploring the impor-
tance and meaning of work for patients [34, 35] serve to un-
derline the salience of this area. Qualitative studies demon-
strate that roles and responsibilities outside of work (i.e. being
a parent or carer for others) are also a significant part of pa-
tients’ lives and that cancer has consequent interaction and
impact on these [36–40]. Wright and colleagues [41] conduct-
ed a robust study with patients using focus groups and inter-
views to describe and categorise cancer patients’ social diffi-
culties. A total of 32 social problems were identified which
were able to be categorised under eight headings: (1) manag-
ing in the home, (2) health and welfare services, (3) finances,
(4) employment, (5) legal matters, (6) relationships, (7) sexu-
ality and body image and (8) recreation. This literature sug-
gests a breadth of social aspects of patients’ lives impacted by
cancer that is not traditionally captured alongside treatment
toxicity and disease burden, endorsing the need for a further
literature search focussed on PROs covering the areas not so
well accounted for by the commonly used HRQoL measures.
The current review aims to provide summary and evalua-
tion of PROMs used in studies for reporting the impact of
cancer on wider social aspects of patients’ lives, particularly
those which may be salient to living with the illness for an
extended period, in other words, expanding assessments to
look at lifestyle impacts under a conceptual framework which
is in the early stages of delineation and referred to as ‘quality
of survival’ (defined by four interconnected dimensions: sur-
vival, quality of life, side effect management and economic
impact management) [42]. This will highlight what has been
used, and how and where gaps may still exist which could be
addressed with revision or supplementation of currently
employed tools. The focus is on the patient with cancer, not
caregivers nor relatives (see Shilling et al. [43] for a review of
caregiver impact measures).
Methods
Data sources and search
We followed the general principles published by the NHS
Centre for Reviews and Dissemination [44] and carried out
an electronic search of databases to identify publications using
PROs to evaluate the impact of cancer on social aspects of
patients’ lives, specifically financial, lifestyle and
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occupational circumstances, along with roles and responsibil-
ities with dependents (looking after young offspring, a spouse
or elderly parents).
Searches were run in MEDLINE (MEDLINE(R) in-
p roces s and o the r non- indexed c i t a t i ons and
MEDLINE(R) 1946-present) and EMBASE (1947-
present) (both via OvidSP) and CINAHL (1937-
present) and PsycINFO (from 1800s–present) (both via
EBSCOhost). Terms were modified as appropriate for
each database and limited to English language only. A
combination of controlled syntax (MeSH) and free-text
terms were used. Two groups of terms were generated
describing (i) the population and (ii) social aspects of
interest. The terms within each group were combined
with a Boolean OR command and were searched in
combination using a Boolean AND command. Searches
were run on 5 March 2015 and an update conducted 8
January 2016 (see Box 1 for the search strategy used
for MEDLINE, adapted for other databases). The refer-
ence lists of pertinent review articles were also checked
for relevant articles.
Box 1: Search strategy used in MEDLINE and adjusted for other
databases
1. exp neoplasm/
2. (neoplasm* or cancer).mp.
3. 1 or 2
4. (‘role burden*’ or ‘impact on leisure’ or ‘impact on lifestyle’ or ‘impact
on life style’ or ‘role responsibilit*’ or ‘carer responsibilit*’ or
‘childcare role’ or ‘childcare responsibilit*’ or ‘childcare burden*’ or
‘impact on social life’ or ‘social impact’ or ‘family function’).mp.
5. exp return to work/
6. (‘return to work’ or ‘impact on occupation’).mp.
7. 5 or 6
8. (‘out of pocket’ or ‘out-of-pocket’ or ‘financ* burden*’ or ‘financ*
impact’ or ‘impact on financ*’).mp.
9. 4 or 7 or 8
10. 3 and 9
11. limit 10 to english language
Study selection criteria
Inclusion criteria were articles in the English language on any
quantitative study containing the report of the impact of ad-
vanced (or secondary or metastatic or stages III or IV) cancer,
as assessed by the use of PROs, on the wider social aspects of
adult patients’ lives, that is on financial situation, lifestyle,
occupational circumstances, roles and responsibilities with
dependents (looking after young offspring or elderly parents)
and there was no date restriction.
Excluded were qualitative studies, those with children
or caregivers as the sole participants, those involving
populations with early cancer (i.e. disease stages I or II)
or the very final end-of-life stage; also excluded were
studies focussed on the metrics of an instrument, reviews,
editorials, letters, opinion, reports published on meeting
abstracts and academic theses, any of which an English
language version of the PRO had not been developed.
Pure monetary costing surveys and functional workability
assessment surveys were not included as these give no
information on perceived impact on the patient, e.g. re-
cording in a diary a certain amount of money was spent
on a hospital parking charge does not establish if, or how,
burdensome it was.
A schema for identification and selection of eligible
articles can be seen in Fig. 1. Titles and abstracts were
screened independently by two reviewers (SC and VS)
against the inclusion and exclusion criteria, and any
duplicate papers were recorded and excluded. The full
text of potentially relevant papers were retrieved and
then further scrutinised independently by both reviewers
to identify the final list included in the review. Article
selection disagreements were resolved by discussion and
a third reviewer (LF) provided adjudication if necessary.
Citation chasing
Backwards citation chasing (one generation) using reference
lists of all papers included in the review and forwards citation
chasing (one generation) using Science Citation Index
Expanded and Social Science Citation Index Expanded via
Web of Science were conducted.
Data extraction
For each included paper, the following descriptive data
were extracted into a standardised form: first author
name, publication year, setting/country, study design
and aim, study population (cancer type and demogra-
phy), number of participants, what social factor/s were
assessed and how, reported outcomes and study limita-
tions. Data were extracted and the quality of studies
appraised by one reviewer (RS) and checked by a sec-
ond (SC or VS). Quality appraisal criteria are shown in
Box 2 and were developed in accordance with the prin-
ciples published by the National Health Service Centre
for Reviews and Dissemination [44]. Without evidence
to inform any differential weighting amongst the
criteria, none was applied. A score of one point was
awarded where good evidence was provided to meet a
criterion, a half point if the evidence provided was
weak, and where no evidence was present a zero score
was given. Higher total scores represent better quality
with articles scoring 0–3.5 designated a +, scores 4–7.5
a ++ and 8–12 a +++.
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Box 2: Criteria for assessing the quality of studies
1. Is the aim of the study clear?
2. Is the study design/method appropriate?
3. Are the study eligibility criteria specified?
4. Is participant selection apparently bias free?
5. Is there a power calculation for sample size?
6. Is sample size adequate and response rate satisfactory? (a possible half
point could be given for each)
7. Has a validated measure been used? (i.e. evidence of instrument
development, content and construct validity, test-retest reliability,
ability to detect change)
8. Are data analyses appropriate?
9. Are all study participants accounted for?
10. Is the study apparently free of confounding factors?
11. Are the conclusions supported by the results?
12. Are the results generalizable?
Results
Articles
The initial search yielded 3115 articles; an additional 6
were identified from hand searches (Fig. 1). After remov-
al of duplicates and initial screening of titles and ab-
stracts, 45 full texts were examined; 12 met the inclusion
criteria. A further 8 articles added from the citation
searches and 2 from the electronic search update resulted
in 22 articles included in the review. The characteristics
of the studies are summarised in Table 1, grouped under
three broad subheadings dependent upon the focus of
investigation: financial distress, roles and responsibilities
or multiple aspects of social life. Description of the in-
struments used and study outcomes is summarised in
Table 2.
Duplicate records removed 
n = 360
33 articles excluded 
Reasons:
Impact not quantified n = 12
Reports psychometrics of measure only n = 3
Review/commentary n = 2
Social areas of interest not covered n = 16
Additional articles identified via 
searches of the reference lists of 
pertinent review papers  n = 6
Records retrieved by search strategy  n = 
3115
Records screened on title and abstract 
by 2 reviewers 
n = 2761
Records excluded 
(not meeting inclusion criteria 
and/or meeting exclusion criteria) 
n = 2716
Full text articles retrieved and screened 
by 2 reviewers 
n = 45
Additional articles identified 
through citation searches n 
= 8
Articles included in review n = 22 
Additional articles from 
search update conducted 
08.01.16     n = 2
Fig. 1 Flow chart showing
identification and selection of
eligible articles
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Table 2 Instruments and study outcomes
Instrument and studies Instrument description Main findings
Financial distress
Work, Life and Finances subscale
(study-specific instrument)
Bennett 2009 [45]
Questions:
-25 covering employment, household income,
health insurance
-11 about changes made to work circumstances
(e.g. reduced working hours) within first
6 months after treatment completion
Rating scale: 3-point ‘not at all’, ‘a little’, ‘a lot’
-35 respondents said that they were the main
earner in their household before diagnosis, 26
maintained this after treatment
-Of the 9 who said that they were no longer the
main earner, 5 said that this was due to cancer
-37% reported having a reduced household
income, and all said that this was due to cancer
-72% reported utilising at least one method of
economising
-No one reported going without treatment but
62% reduced or stopped trips to the shops
Financial Questionnaire (author generated)
Delgado-Guay 2015 [46]
Questions:
-4 statements about impact of financial distress
on ‘physical’, ‘social’, ‘spiritual’ and
‘emotional’ well-being
-4 terms, ‘subjective financial burden’,
‘financial concerns’, ‘financial difficulties’,
‘financial worries’
Rating scales:
Statements were scored on 5-point scale
ranging from ‘strongly agree’ to ‘strongly
disagree’
Terms were scored on a 11-point scale with 0
as ‘absent’ and 10 as the ‘worst possible’
-Educational levels differed between the
Comprehensive Cancer Centre (CCC) and the
General Public Hospital (GPH) patients (58
and 19% respectively had college education or
an advanced degree, p < 0.0001), as did
monthly income (median of $3000 versus
$940, p = 0.0017)
-The distribution of race/ethnicity also differed
(p < 0.0001) (62 versus 18% were white at
CCC and GPH respectively, 27 versus 38%
were black and 9 versus 38% were Hispanic).
-Financial distress (FD) was highly prevalent, as
reported by 86 and 90% of patients from the
CCC and GPH respectively
-Median FD scores for the GPH patients were 4
(IQR 1–7) versus 8 (IQR 3–10) for the CCC
patients (p = 0.0003)
-30% of patients had more FD than physical
distress, and there was no significant group
difference
-31% had more FD than distress from physical
functioning, more so for the GPH group (39
versus 23% with p = 0.051)
-43% had more FD than social/family distress,
more so for the GPH group (54 versus 33%
with p = 0.0085)
-37% had more FD than emotional distress, more
so for the GPH group (46 versus 29% with
p = 0.041)
The COST measure
Huntington 2015 [47]
Questions:
-11-item PRO developed for patients with
advanced malignancies covering: ‘having
enough money for treatment costs’,
‘expectation about out-of-pocket medical
expenses’, ‘worry about future financial
problems’, ‘perceived control over money
spent on care’, ‘frustration at inability to
work/contribute’, ‘satisfaction with current
finances’, ‘ability to meet monthly expenses’,
‘feeling financially stressed’, ‘concern about
maintaining job and income’, ‘cancer or
treatment reducing financial satisfaction’,
‘feeling in control of finances’
-1 additional question asking to rate
self-reported level of financial burden
-1 additional question asking to rate
expectation about treatment costs
-list of coping strategies that patients indicate
which if any they employ
-Mean COST score was 23 (s.d. 11.1), and the
median (23.5) was used to stratify higher
financial burden (COST score ≤ 23) versus
lower (score > 23)
-71% reported at least minor financial burden
-59% of indicated treatment costs were higher
than expected, more so for those with higher
financial burden than lower (76 versus 42%
respectively, p = 0.00057)
-46% used savings to pay for treatment, 21%
borrowed money to cover treatment costs and
17% reported treatment delays due to cost
-36% applied for financial assistance; this did not
differ significantly between higher and lower
financial burden groups
-Patients with higher financial burden were more
likely to employ general financial coping
strategies, e.g. reduce spending on basic goods
and leisure activities, use savings for care,
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Table 2 (continued)
Instrument and studies Instrument description Main findings
Rating scales:
-The COST measure has a 5-point scale
0 = ‘not at all’, 1 = ‘a little bit’,
2 = ‘somewhat’, 3 = ‘quite a bit’, 4 = ‘very
much’ (scores are totalled and range between 0
and 44 with lower scores indicative of greater
burden)
-Self-reported level of financial burden rated
on a 4-point scale ‘not at all’, ‘minor’,
‘moderate’, ‘significant’
-Expectation about treatments costs rated on
3-point scale ‘lower than expected’, ‘as
expected’, ‘higher than expected’
borrow money to pay for treatment (all
ps < 0.0001)
-Patients with higher financial burden were more
likely to employ treatment-related financial
coping strategies, e.g. delay treatment initiation
(p = 0.0030), fill only part of a myeloma
therapy prescription (p = 0.0077), stop
myeloma therapy (p = 0.0011), skip a clinic
visit to save on costs (p = 0.027)
-Younger age (p = 0.00092), non-married status
(p = 0.0074), longer time since diagnosis
(p = 0.042) and lower household income
(p = 0.0031) were associated with higher
financial burden on the COST measure in
multivariate analysis
Personal Financial Wellness (PFW) Scale
-formally known as ‘The Incharge Financial
Distress/Financial Well-Being Scale’
Meisenberg 2015 [48]
Questions:
-8-item PRO that assesses financial distress
covering ‘level of financial stress today’,
‘satisfaction with present financial situation’,
‘level of comfort with current financial
situation’, ‘frequency of foregoing a social
activity, e.g. eating out, seeing a movie’,
‘frequency of having to live paycheck to
paycheck’, ‘frequency of worry about meeting
normal monthly living expenses’, ‘confidence
in ability to pay for a financial emergency’,
‘general level of stress due to finances’
-1 additional dichotomous item asked ‘have
you changed your spending habits, e.g.
reduced leisure spending due to care costs?’
-1 additional item asked to what extent do you
agree with the statement ‘I believe that being
sick has or will hurt me financially’
Rating scales:
-Each item on the PFW is rated on a 10-point
scale of 1–10 (some items are reverse scored)
-Lower scores on the PFW indicate greater
financial distress and recommended cutoffs
provide categories of ‘high distress’ (scores
<4.4), ‘average distress’ (scores 4.5–6.4), ‘low
distress’ (scores >6.5)
-The item on financial hurt was rated on a
5-point scale from 1 = ‘strongly disagree’ to
5 = ‘strongly agree’
-Mean financial distress score was 5.11 (s.d. 2.77)
compared to a general population mean of 5.7
(lower score indicating greater distress) -47%
of participants reported high levels of financial
distress
-50.4% of participants agreed or strongly agreed
that being sick had hurt them financially
-52.3% had changed their spending habits as a
result of treatment costs
-6.1% had reduced medication adherence due to
costs
-25.8% had increased their debt, 22% had lapsed
on bills and 1.5% had declared bankruptcy
-Those with higher income were less likely to
have endorsed experiencing financial impact
from treatment (p < 0.001, CI −0.53 to −0.18)
-Marital status, medical insurance status,
treatment and age were not associated with the
perception that treatment had resulted in a
financial impact
Breast Cancer Finances Survey (adapted from
Given 1994 [67])
Meneses 2012 [49]
Questions:
-4 items about changes in work( work
motivation, productivity, quality and missed
work days)
-15 items about financial hardship (i.e. income
reduction, sold house, used up savings, spouse
lost wages due to caring duties, etc.)
Rating scale: each item was endorsed with a
binary ‘yes’/’no’ response
-Over 50% of participants reported at least one
economic burden event related to either their
work or a financial hardship within 6 months
following treatment completion
-Items most endorsed at baseline were
productivity at work (27%), missing days
(38%), sacrificed leisure, e.g. holidays (40%),
income reduction (35%) and used savings
(27%)
-Participants reported a mean of 2.94 burden
items at baseline, 2.45 at month 3 and 2.25 at
month 6
-The endorsement of 5 items significantly
decreased from baseline to 6 months: reduced
work motivation (23 to 12%, p = 0.016),
productivity (27 to 12%, p = 0.002), quality
(17 to 7%, p = 0.01), missing days (38 to 19%,
J Cancer Surviv
Table 2 (continued)
Instrument and studies Instrument description Main findings
p < 0.001) and sacrificed leisure, e.g. holidays
(40 to 31%, p = 0.001)
-The item, ‘increase in health insurance
premiums’, was increasingly endorsed across
the 6 months (7 to 16%, p = 0.022)
Financial Questionnaire (author generated)
Pisu 2015 [50]
Questions:
-1 item about current level of financial
difficulty: ‘how difficult is it to live on the
household income right now?’
-2 about anticipated financial difficulty: ‘how
much will family experience financial hardship
in next 2 months?’ and ‘how much will
standards of living have to be reduced in next
2 months?’
Rating scales:
-Current financial difficulty scored on a 5-point
scale (‘not at all’, ‘somewhat’, ‘difficult’,
‘very’ and ‘extremely’)
-Anticipated financial difficulty items scored
on a 4-point scale (‘not at all’, ‘a little’,
‘moderately’, ‘a great deal’)
-For the purposes of analysis all response
scores were dichotomised with 0 for ‘not at all’
and 1 for all other scores beyond ‘not at all’
-In both the lung cancer (LC) and the colorectal
cancer (CC) cohorts, patients of minority
race/ethnic background had lower incomes
(p < 0.05) and were less likely to have
prescription drug coverage (p < 0.05)
-Across all participants, ≥40% reported financial
hardship (defined as having current difficulty
with household income or anticipating
financial hardship or anticipating having to
reduce standards of living)
-Minority races reported greater financial
hardship in both the LC (white 50%,
African-American 69%, Hispanic 59%,
p < 0.05) and CC (white 41%,
African-American 67%, Hispanic 59%,
p < 0.05) cohorts
-In statistical modelling, lack of prescription drug
coverage and lower income were associated
with financial hardship and it was suggested
could explain to some extent the racial/ethnic
disparities
Financial Questionnaire (author generated)
Regenbogen 2014 [51]
Questions:
-7 items covered financial adjustments made
due to disease (‘used savings’, ‘borrowed
money’, ‘couldn’t pay bills/credit cards’,
‘spent less on food/clothing’, ‘less spent on
other family health’, ‘spent less on leisure’,
‘generally spent less’
-1 item about financial worry (‘how much do
you worry about financial problems resulting
from your cancer/treatments?’)
Rating scales:
-The 7 financial items required a binary
response ‘yes’ or ‘no’ and these items were
summed to give a composite measure of
financial burden (range 0–7)
-Financial worry was scored on a 5-point scale
1 = ‘not at all’ to 5 = ‘very much’ (scores of
1–3 were considered ‘low worry’ and scores of
4–5 ‘high worry’)
-38% reported making no financial adjustments
on the composite burden measure, 29%
endorsed 1–2 items, 22% 3–4 items and 11%
5–7 items
-Higher financial burden scores were
significantly associated with higher financial
worry (p < 0.001)
-Patients with self-reported post-operative
complications were more likely to endorse
items of financial burden (70 versus 59%
endorsed 1 or more burden items, p < 0.001);
NB 24% of patients said they had
complications
-Those with complications reported higher levels
of financial worry (61 versus 52%, p = 0.01)
-Multiple regression showed that location
(metropolitan versus others), age, income,
chemotherapy and health status were all related
independently to financial burden
-The relationship between financial burden and
complications remained after controlling for
the above covariates plus sex, race, marital
status, education and co-morbidities (crude
scores 2.15 versus 1.66, p = 0.03; adjusted
scores 2.21 versus 1.69, p < 0.001)
Cost of Head and Neck Cancer Questionnaire
(author generated following review of
SDI-21 and EORTC-QLQ-C30 instruments)
Rogers 2011 [52]
Questions:
-1 item asking if working status had been
affected by cancer
-17 items covering common life expenses (e.g.
food, heating, travel, childcare, mortgage,
clothes)
-1 question to nominate the 3 life expenses,
from item list of 17 common life expenses,
most impacted by cancer and indicates if
-31% of respondents said cancer had affected
their working status
-54% of respondents had at least one moderate or
large burden and 17% had at least 5
-More patients under 65 years indicated at least 3
financial issues that were moderate or large
burdens (48% of 55 years old, 44% of
55–64 years old, 21% of 65–84 years old,
p < 0.001)
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statutory financial help had been sought and
received
-5 items scored for difficulty experienced
within the past month: work or if student
education, planning for the future, living
environment (e.g. housing conditions),
benefits (e.g. sick pay) and financial services
(e.g. mortgage)
-1 item on satisfaction with coping with own
finances
-1 item about financial difficulty in the past
week
Rating scales:
-5-point burden scale ‘none’, ‘little’,
‘moderate’, ‘large’ or ‘not applicable’ for
rating common life expenses
-4-point difficulty in the past month scale ‘no
difficulty’, ‘a little’, ‘quite a bit’, ‘very much’
-6-point satisfaction with financial coping
scale ‘very satisfied’ to ‘very unsatisfied’
-4-point financial difficulty scale ‘not at all’, ‘a
little’, ‘quite a bit’, ‘very much’
-The most notable financial costs that were a
moderate or large burden to patients were
expense on petrol (25%) and home heating
(24%)
-39% of patients applied for state financial
assistance, as a result of cancer, with 71% of
these receiving help
-25% were moderately or very dissatisfied about
coping with their finances
-Those with worse physical and social-emotional
functioning experienced more financial
burden, difficult life circumstances in the past
month, financial difficulty and loss of earnings
in the past week were more dissatisfied with
their financial coping and sought more state
financial help
Financial Measure (author generated)
Sharp 2013 [53]
Questions:
-1 question assessed the patient’s perception of
the impact of the cancer diagnosis on the
household’s ability to make ends meet, i.e.
difficulty of making ends meet (labelled
‘financial stress’)
-1 question assessed how concerned the patient
felt about their household’s financial situation
since their cancer diagnosis (labelled ‘financial
strain’)
Rating scale: 7-point scale ‘much more
difficult/very concerned’ to ‘much less
difficult/less concerned’
-49% reported increased financial stress and 32%
increased financial strain due to the cancer
-Depression was raised twofold to threefold in
those reporting increased cancer-related
financial stress (OR = 2.79, 95% CI
1.87–4.17) and strain (OR = 3.56, 95% CI
2.23–5.67)
-Anxiety was raised threefold and greater in those
reporting increased cancer-related financial
stress (OR = 3.44, 95% CI 2.21–5.35) and
strain (OR = 4.43, 95% CI 2.65–7.39)
Financial Questionnaire (author generated)
Zafar 2013 [54]
Questions:
-1 subjective financial burden question ‘how
much financial burden has resulted from
cancer-related out-of-pocket expenses?’
-7 descriptions of ways to alter obtaining
prescription medication to reduce costs, e.g.
shop at cheapest pharmacy
-3 descriptors of lifestyle changes to assist
coping with financial impact of prescription
medications, e.g. spend less on food
-3 descriptors of ways to alter medication use
to reduce costs, e.g. take less than prescribed
amount
-5 descriptors of ways to alter care to reduce
costs, e.g. cancelling clinic appointment
-7 descriptors of lifestyle changes to assist
coping with financial impact of care services,
e.g. sold possessions
Rating scales:
-5-point financial burden scale ‘not at all’,
‘minor’, ‘moderate’ ‘significant’,
‘catastrophic’
-For all coping strategy descriptors, a binary
response ‘used’ or ‘not used’
-42% reported a significant or catastrophic
subjective financial burden
-To reduce medication costs 55% obtained
samples from doctor, 48% asked for a cheaper
drug to be prescribed, 47% shopped around for
lowest drug prices and 19% took less than
prescribed amount
-Most frequent lifestyle changes made to save
money were reduced leisure activities (68%),
cut-backs on food and clothing (46%), using
savings (46%) and borrowing money/using
credit (35%)
-Higher subjective financial burden was
associated with application for statutory
financial help (p = 0.007) and talking to the
doctor about care costs (p = 0.02)
-Lower subjective financial burden was
associated with age ≥65 years (p < 0.001) and
smaller household size (p = 0.008)
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Roles and responsibilities
Parenting Concerns Questionnaire (PCQ)
Moore 2015 [55] (N.B. this paper also used the
Parental Efficacy Beliefs Scale, see below)
Park 2015 [56]
Questions:
-Practical Impact subscale of 5 items about
concerns relating to the practical impact of the
parent’s illness on the child
-Emotional Impact subscale of 5 items about
concerns relating to the emotional impact of
the parent’s illness on the child
-Concerns about co-parent subscale of 5 items
about concerns relating to co-parent’s abilities
to perform their role
Rating scale:
-5-point scale 1 = ‘not at all concerned’ to
5 = ‘extremely concerned’
-ratings from all 15 items can be summed for a
total score, and scores for the 3 subscales can
also be calculated and reported
Moore 2015
-Higher PCQ total score and greater concerns
on the practical and emotional subscales were
all associated with decline in parental efficacy
(as rated using Parental Efficacy Beliefs Scale
below)—all ps < 0.001, but not the co-parent
concerns scale
-Decline in patients’ perceptions of co-parent
efficacy was also associated with total PCQ
score (p < 0.001), practical impact scale
(p < 0.01), and co-parent concerns scale
(p < 0.01), but not the emotional impact scale
Park 2015
-Mean total score was 2.3 (s.d. 0.9) reflecting
‘mild’ to ‘moderate’ concerns
-Means for the subscales were practical
subscale 2.5 (s.d. 1.1), emotional subscale 2.5
(s.d. 1.1) and co-parent subscale 1.8 (1.0)
-Higher PCQ scores were associated with
single marital status (p = 0.05), poor
functional status (p < 0.001), poorer quality of
life (p < 0.001), anxiety (p < 0.001),
depression (p < 0.002) and lack of social
support (p < 0.002)
-The highest scoring worries patients had were
‘how their child would cope with their death’
(mean 4.0, s.d. 1.2), ‘current emotional impact
of their illness on their child (mean 3.3, s.d.
1.2) and the emotional impact of the disease on
their partner (mean 3.1, s.d. 1.3)
Parental Efficacy Beliefs Scale (author
generated)
Moore 2015 [55]
Questions:
-1 item asking the patient ‘how well were you
able to meet your children’s needs before
diagnosis?’
-1 item asking ‘how well are you now able to
meet the needs of your children now?’
-2 further items rate the patient perceptions of
the co-parent meeting the needs of the children
before and after diagnosis
Rating scale: 5-point scale (‘not well at all’, ‘not
that well’, ‘well enough’, ‘very well’,
‘extremely well’)
-60% of patients felt that they had met their
children’s needs ‘extremely well’ before
diagnosis, but only 11% felt this way after
diagnosis
-42% of patients felt their co-parent had met their
children’s needs ‘extremely well’ before
diagnosis; 26% felt so afterwards
-Mean scores for patients’ parenting efficacy
dropped significantly after diagnosis
(before = 4.53 (s.d. 0.63) versus after = 3.4
(s.d. 0.88), p < 0.0001); for co-parent, efficacy
rating dropped from 3.89 (s.d. 1.20) to 3.57
(s.d. 1.28), p < 0.0001
-Mean parental efficacy change score was −1.13
with no significant difference between mothers
and fathers. For co-parents, this was −0.32 and
fathers perceived a bigger decline in their
partner’s ability after diagnosis than mothers
did
-Decline in parental efficacy was associated with
more frequent medical clinic visits
(p = 0.001), poorer health-related quality of
life (p < 0.001) and depression (p < 0.001)
CARES Marital and Relationship with
Children subscale
Walsh 2005 [57] (adapted the time frame so that
patients were asked to respond reflecting on
the time since diagnosis rather than ‘in the past
month’ which is standard for administration)
Questions:
-18-item ‘Marital subscale’ about woman’s
relationship with her spouse/partner covering 5
domains (communication, affection,
interaction, partner neglect and overprotection)
-On the Marital subscale, the communication
domain had the highest mean (1.26, max score
4) score indicating the most problematic area
-The most frequently endorsed items for being a
problem within spouse/partner communication
were ‘talking about what may happen after the
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-3-item ‘relationships with children subscale’
about communication with and taking care of
children
Rating scale: 5-point scale (0 = ‘not at all’ to
4 = ‘very much’) with higher scores indicative
of greater problems
patient’s death’ (52.8%) and ‘talking about
cancer’ (37.4%)
-On the Marital subscale the other domains of
affection, intimacy, neglect and partner
overprotection were not reported as
problematic by many women
-The overall mean for the relationships with
children was low (0.69, max score 4), but
percentages of women indicating a problem
(scoring ‘fair amount’, ‘much’ or ‘very much’)
on the individual items showed that 19.7% had
difficulty with ‘helping their children talk
about their cancer’, 16.8% ‘helping their
children cope’ and 12.7% ‘taking care of their
children as a result of having breast cancer’
Multiple aspects of social life
Illness intrusiveness ratings scale (IIRS)
De Groot 2005 [58]
Devins 2006 [59] andMah 2011 [60] (N.B. these
papers report different analyses of the same
data set)
Schimmer 2001 [62]
Sohl 2014 [64]
Questions:
-13-item scale measuring degree to which a
person’s illness and/or treatment interferes
with 3 life domains
-Instrumental domain (4 items): health, work,
active recreation, e.g. sport, financial situation
-Intimacy domain (2 items): sex life,
relationships with spouse/partner
-Relationships/personal domain (6 items):
passive recreation, e.g. reading, or listening to
music, family relationships, other social
relationships, self-expression/improvement,
community and civic involvement, religious
expression
-1 independent item about diet
Rating scale: 7-point (1 = ‘not very much’ to
7 = ‘very much’)
De Groot 2005
-Illness intrusivenesswas greater for those with
advanced disease than early stage (mean 3.6
concerns, 95% CI = 2.8–4.5 versus mean 2.5
concerns, 95% CI = 1.8–3.2, p < 0.049)
-Most frequently reported concerns were
prognosis and intimacy (sex life and spousal
relationship)
-Illness intrusiveness associated with treatment
being more recent where treatment completion
<12 months ago was associated with more
concerns than if treatment was completed
>12 months ago (mean 3.5 concerns, 95%
CI = 2.8–4.2 versus mean 2.2 concerns, 95%
CI = 1.3–3.1, p < 0.049)
-The illness intrusiveness reduction associated
with greater time since treatment completion
showed an interaction that was followed up by
post-hoc Tukey’s B tests. This indicated the
significant reductions occurred in only 3 areas:
communication with the treatment team,
relationship with spouse/partner, relationship
with others
Devins 2006
-Higher rates of illness intrusiveness were
reported by patients who were younger
(p < 0.014), on a lower income (p < 0.002)
and who had experienced one or more stressful
life events (p < 0.014)
-On average illness intrusiveness was reported
as highest for the instrumental domain (3.4,
CI = 3.2–3.5), followed by intimacy (2.8,
CI = 2.6–3.0) and then relationships/personal
(2.2, CI = 2.1–2.3)
-There was a main effect of cancer type
modifying levels of intrusiveness (p < 0.004)
with highest scores for gastrointestinal
(mean = 3.4) and lowest for prostate
(mean = 2.2)
-There was also a significant interaction
between type of cancer and illness
intrusiveness domain (p < 0.0005). All cancer
types except prostate reported illness
intrusiveness highest for the instrumental
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domain, followed by intimacy and then
relationships/personal
-For patients with prostate cancer illness
intrusiveness was highest for the intimacy
domain, followed by instrumental, and then
relationships/personal
Mah 2011
-Women, regardless of type of cancer, reported
highest illness intrusiveness for the
instrumental domain (mean = 3.39), followed
by intimacy (2.49), then relationships/personal
(2.27). The type of cancer had no interactive
effect and all of the differences between
domains were significant (all ps ≤ 0.03)
-Men with prostate cancer reported
significantly lower total illness intrusiveness
than men with either gastrointestinal (36.63
versus 28.56, p = 0.01) or lung cancer (39.00
versus 28.56, p = 0.001). No other significant
cancer type group differences were evident for
total scores
Schimmer 2001
-Mean total illness intrusiveness score = 37.2
(s.d. 17.6) for patients with blood/bone
marrow transplantation
-Higher illness intrusiveness was associated
with receiving transplantation more recently
(p = 0.01), with depression (r = 0.48,
p < 0.0001), and hopelessness (r = 0.58,
p < 0.0001); lower levels with positive affect
(r = −0.54, p < 0.0001) and happiness
(r = −0.44, p = 0.004)
-No significant correlations between illness
intrusiveness and age, gender, education,
underlying diagnosis (myeloma, leukaemia,
Hodgkin disease or breast cancer), or
employment
Sohl 2014
-92% had early stage disease
-The majority (52–65%) of these women with
breast cancer reported low levels of illness
intrusiveness in all three domains during the
2 years since treatment
-The instrumental domain showed most (52%)
had constantly low scores, 34% started high
and decreased over time and 14% had scores
that remained high throughout
-The intimacy domain showedmost (60%) had
constantly low scores, 30% started high and
decreased over time and 10% had scores that
remained high throughout
-The relationship/personal domain showed that
most (65%) had constantly low scores, 9%
started high and decreased over time, 9%
started low and increased over time, 10% had
high scores throughout
-Being older, not having children <18 years at
home, having stage 1 disease, having fewer
symptoms and better psychosocial well-being
were all associated with constantly low illness
intrusiveness (all ps < 0.05)
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Social and Financial Impacts Questionnaire
(author generated)
Paul 2013 [61]
Questions:
-5 items related to social impact: ‘had reduced
access to children’, ‘needed help to care for
family’, ‘missed family events/children’s
activities’, ‘missed important social or
religious activities’, ‘lost contact with friends’
-6 items related to financial impact: ‘time-off
work’, ‘income loss’, ‘job loss’, ‘bills payment
problems’, ‘daily expenses problems’, ‘used
up savings’
-9 items related to personal expenses incurred:
‘hospital travel’, ‘hospital accommodation’,
‘hospital parking’, ‘drugs/treatments’, ‘other
medical supplies’, ‘own homecare’,
‘childcare’, ‘other dependant’s care’,
gardening/housework’
-8 items related to things that could reduce
social and financial impacts: ‘local treatment’,
‘out-of-hours clinic times’, ‘weekend clinics’,
‘free hospital parking’, ‘free hospital
transport’, ‘free medications/treatments, ‘direct
financial support’, ‘none’
Rating scale: on each of the 3 lists, participants
select all those items that are relevant
-64% of participants reported at least one
cancer-related financial or social impact in
their lives; most frequently reported were
time-off work (44%), reduced income (31%),
missing family events (23%) and difficulty
paying bills (21%)
-Metropolitan respondents reported significantly
more financial impact than their
non-metropolitan counterparts (p = 0.014),
but no similar difference was evident for social
impact
-Individuals at a higher risk of experiencing
financial or social impacts were younger,
employed, stressed and reported a personal
expense
-45% said a cancer related out-of-pocket expense
had been incurred in the past month including
paying for: hospital/clinic parking (33%),
travel to medical appointments (30%),
treatment drugs (24%), home help or gardener
(8%)
-58% reported at least one item that would (was it
to be available) have reduced the social and
financial impacts of the disease on their daily
life; most frequently endorsed were free
hospital parking (37%), free
medications/treatments (29%) and access to
treatment locally (20%)
Social Difficulties Inventory (SDI-21)
Simon 2008 [53]
Wright 2005 [65] (provides an overview of data
from three separate studies)
Wright 2015 [66] (only included participants
who had completed all of the SD-16 but did
report on the full SDI-21 for these individuals)
Questions:
-21 items covering a range of everyday
difficulties commonly encountered by patients
with cancer. The inventory is subdivided into:
-Everyday living subscale (6 items) about:
independence, domestic chores, personal care,
care of dependents, getting around, recreation
-Money matters subscale (5 items) about:
welfare benefits, finances, financial services,
work, planning the future
-Self and other subscale (5 items) about:
support for close relatives, communication
with close relatives, communication with
others, body image, isolation
-5 standalone items about: sex, plans to have a
family, discrimination due to the illness, living
conditions, holidays
Rating scale:
-4-point scale rating difficulty from 0 = ‘no’ to
3 = ‘very much’
-A summary score of the 16 items on the 3
subscales can be reported (SD-16)
-3 subscales can be individually reported
Simon 2008
-Having invasive disease (p < 0.001), surgery
(p < 0.01) and chemotherapy (p < 0.001)
were associated with reporting more social
difficulties
-Within 2 months of diagnosis, those with
lower socioeconomic status (SES) had more
social difficulties (mean 10.2 versus 8.0,
p < 0.01), and this difference persisted after
controlling for age, gender, disease site and
stage and treatments received
-A significant decrease in social difficulties
was shown at 10 months follow-up (mean 7.9
versus 5.5, p < 0.001), and the apparent
disparity between low and high SES had
disappeared by follow-up as there was no
interaction for SES
Wright 2005
-The authors reported that cancer and cancer
treatments at all stages had an impact on social
aspects of patient’s lives with 275/609 (45%)
reporting high levels (summary score ≥ 9) of
difficulty
-Stage of disease (p < 0.0001), age
(p < 0.009) and deprivation (p < 0.048)
significantly influenced prevalence of social
difficulties (younger patients, those with more
advanced disease and, to a lesser extent, those
from more deprived areas reported more
difficulties)
-An interaction between stage of disease,
deprivation, age and sex was found
(p < 0.015); post-hoc analysis on this
interaction showed that significantly more
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Most articles comprised single time-point surveys covering
a broad array of tumour sites. The majority examined mixed
tumour groups, but 7/22 reported on single disease groups.
Sample size varied widely, ranging from 26 to over 21,000
patients. Overall, sex representation was clearly specified for
all of the studies, but details of participants’ ages were less
consistently provided. Most of the studies had been conducted
within a time frame of the first 3 years following diagnosis.
Some study samples were early disease, some clearly ad-
vanced disease and others a mixture or details were not pro-
vided within the article; however, no specification of stage
was made in the inclusion criteria for the current review.
Quality of publications
Marked against the quality criteria in Box 2, and reported in
Table 1, only four studies scored highly (+++) [47, 57, 65, 66].
Some individual criteria warrant specific comment. Only 8
studies were rated as having bias free participant selection, 8
were rated as being apparently free of confounding factors and
11 accounted for all participants in their reporting. Of partic-
ular note was the use of diverse, non-validated, study-specific
instruments to investigate financial distress; only two of 10
studies used a validated measure.
Financial distress
Table 2 details the 10 articles [45–54] that reported on self-
perceived financial distress. Only two used a validated
measure. One [47] employed ‘The COST measure’ [68], a
recently developed 11-item tool validated in patients with ad-
vanced cancer and available via the Functional Assessment of
Chronic Illness Therapy (FACIT) suite of questionnaires (see
www.facit.org). The second [48] used the ‘Personal Financial
Wellness (PFW) Scale’ [69] (formally known as the ‘Incharge
Financial Distress/Financial Well-Being Scale’ [70]), which
has 8 items, is validated and has been used with cancer pa-
tients but without normative data [71]. The remaining eight
studies [45, 46, 49–54] used un-validated study-specific tools.
The number of questions used in these non-validated mea-
sures varied widely, and the content of the items across the
measures was diverse and highly individual. Outcomes from
the 10 articles show the presence of much self-perceived fi-
nancial distress amongst the study participants. The findings
also demonstrated strategies frequently employed by patients
to mitigate their financial burden, including financial reduc-
tions to health-related areas and more generally with clothing,
food and leisure. Additionally, patients borrowedmoney, used
credit and defaulted on bills. Factors repeatedly associated
with greater financial burden were younger age, lower in-
come, poorer health status, more treatment/s, non-white eth-
nicity and poorer psychological well-being (i.e. greater anxi-
ety and depression).
Roles and responsibilities
Three articles [55–57] investigated the impact on patients’
roles and responsibilities in everyday life. Two [55, 56] used
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social difficulties were reported by less affluent
patients with locally recurrent disease
(p = 0.003) and by less affluent survivors, i.e.
patients cancer free for >2 years (p = 0.016)
Wright 2015
-2688/17,830 (15.1%) were classified as
socially distressed (summary score ≥ 10)
-19.5% had difficulties with everyday living
(score ≥ 5), 15.6% had difficulties with money
matters (score ≥ 2) and 18.1% had difficulties
with self and others (score ≥ 3)
-Multiple regression analysis showed that the
strongest predictor for social distress was
having ≥3 long-term co-morbidities, followed
by unemployment, recurrent or non-treatable
disease and having a permanent stoma
-Additional predictors of social difficulties
were younger age (<55 years), living in a more
deprived area, non-white ethnicity, tumour site,
having advanced disease, having had surgery,
radiotherapy or chemotherapy and being a
carer (all ps < 0.001)
s.d. standard deviation
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the ‘Parenting Concerns Questionnaire’ (PCQ) [72]. Park and
colleagues [56] found that patients had mild to moderate con-
cerns about their cancer affecting their parental role, this was
both in terms of performing the usual practical things parents
do for their children, but was also about the emotional conse-
quences for the child. Of particular concern was how the child
would cope with their death, impact of cancer on the child’s
emotions and impact on the co-parent’s emotions. Factors
associatedwith higher levels of concerns about parenting were
single marital status, poor functional status, poorer quality of
life, psychological distress (anxiety and depression) and lack
of social support.
Moore et al. [55] combined the use of the PCQ with anoth-
er tool, the ‘Parental Efficacy Beliefs Scale’, a non-validated
instrument measuring patients’ perceptions of their own abil-
ity, and that of their co-parent to perform the parental role.
Most (60%) felt they had been extremely well able to perform
their parenting responsibilities before diagnosis, dropping to
11% after. Similarly, patients reported less belief in the co-
parent after diagnosis (42% dropping to 26%). Factors asso-
ciated with reported decline in parental efficacy were more
frequent clinic visits, poorer quality of life and depression.
Higher levels of parenting concerns expressed on the PCQ
were accompanied by decline in patients’ belief about them-
selves and their co-parent being able to parent.
Walsh et al. [57] investigated the impact for women with
breast cancer on their roles as wife and mother using the
‘Marital’ and ‘Relationship with Children’ subscales from
the CARES instrument [73]. Talking to their spouse/partner
about what may happen after their death was problematic for
52.8% of the women, and 37.4% indicated that just talking
about cancer with them was difficult. Levels of reported dif-
ficulty on the Relationship with Children subscale were not
high; however, 19.7% reported problems helping their chil-
dren talk about their cancer, 16.8% helping their children cope
and 12.7% taking care of their children as a result of breast
cancer.
Multiple aspects of social life
Nine articles used multidimensional instruments [58–66, N.B.
59 and 60 used the same data set]. Five [58–60, 62, 64]
utilised the illness intrusiveness rating scale (IIRS) [74], a
validated tool which measures the extent to which an illness
and/or treatment affects the patient’s social life. Greater levels
of intrusiveness were found to be associated with advanced
disease, younger age, lower income, cancer type, recent treat-
ment and poor psychological well-being (depression and
hopelessness). Conversely, being older, not having children
under 18 years living at home, having early stage disease,
fewer symptoms and better psychosocial well-being
were all associated with consistently low levels of ill-
ness intrusiveness. [64].
The finding that cancer and its treatments commonly im-
pact the social aspects of patients’ lives was evident in three
papers [63, 65, 66] that had used the Social Difficulties
Inventory (SDI), a validated and psychometrically tested in-
strument [10, 75–78]. In one article with pooled data from
three studies, 45% of participants reported high levels of so-
cial difficulty, which was associated more with younger age,
those with advanced disease and, to some extent, those from
deprived areas [65]. In another study, greater social difficulties
were found to be associated with invasive disease (lymph
node involvement or distant metastases), undergoing surgery,
receiving chemotherapy and lower socioeconomic status, and
a reduction in difficulties occurred by 10 months follow-up
with the apparent disparity between low and high socioeco-
nomic status groups disappearing [63]. Results from nearly
18,000 patients endorsed previous reports that predictors of
social difficulties include younger age, living in a more de-
prived area, having advanced disease and undergoing surgery
or chemotherapy [66]. This study also found additional pre-
dictive factors were tumour site, non-white ethnicity, receipt
of radiotherapy and being a caregiver. The strongest predictor
for social distress was found to be having ≥3 long-term co-
morbidities, followed by unemployment and recurrent or non-
treatable disease.
Social and financial impacts were also reported using a non-
validated questionnaire in a study contrasting rural and urban
cancer patients’ experiences [61]. Sixty-four percent of pa-
tients experienced at least one financial or social consequence,
most frequently this was time-off work (44%), reduced income
(31%) and missing family events (23%). City dwellers report-
ed significantly more financial impact, but no similar differ-
ence was evident for social impact. Those who were younger,
currently working and suffering stress, were found to be at
higher risk of experiencing financial or social impacts.
Discussion
Though the studies reviewed here were diverse in terms of
study objectives, methods and patient populations, the
patient-reported outcomes reported by them repeatedly show
cancer and its treatments have significant impact on patients’
finances, roles and responsibilities and on the various facets of
their social life.
Moreover, the findings complement reports from published
quantitative studies [26–33] that have asked patients to report
impact objectively (e.g. by reporting how much money they
have spent on an item such as a medication, by indicating the
time point of return to work or by indicating ability to perform
work tasks) and qualitative studies [34–40] providing first-
hand patient accounts of burden. All of this together under-
lines the far broader nature of the aspects of patients’ social
lives that are impacted than can be assessed by relying solely
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on a social function subscale from one of the validated
HRQoL instruments frequently in use, e.g. EORCT-QLQ-
C30 [6] or FACT-G [7].
The studies reviewed which have attempted to quantify
patients’ self-perceived financial distress have all done so
using different, and in the majority of cases [45, 46, 49–54],
study-specific measures. This has led to diverse and highly
individualised content all scored with incomparable rating
scales. This makes summarising findings across studies prob-
lematic. However, interest and concern regarding financial
burden for patients with cancer have been growing recently
[24], driven by the rapid pace of change where expensive
novel drugs and living longer with incurable disease are now
integral to the picture. In response to this pressure, at least one
validated PRO, the COST measure [68], has been developed.
To improve the quality of studies conducted and data collected
in the future, validated instruments such as this need to be
consistently and widely used. This may help researchers and
healthcare professionals to better explore, understand and help
ameliorate financial distress that patients may experience as a
consequence of their cancer and treatments. The current re-
view highlights a paucity of work regarding PROs used to
quantify the impacts on patients’ everyday roles and respon-
sibilities in life as a result of cancer and its treatments. Only
three studies [55–57] were found, each exploring the impact
on the parental role with validated tools. However, data are
predominantly from female participants (see Table 1) which
should be addressed with future work. The impact on any
role/responsibility a patient might have towards other depen-
dants such as elderly parents or an incapacitated spouse/
partner was covered with only a single generic item on the
SDI, ‘Have you had difficulty with looking after those who
depend on you? (e.g. children, dependent adults, pets)’. Yet,
evidence suggests that these aspects need to be included in our
evaluations; exploratory qualitative analysis has shown that
older women with breast cancer who cared for others strug-
gled to balance caregiving responsibilities and their own
health needs [36]. In another study, women with early-stage
breast cancer andmultiple caregiving roles were found to have
elevated depressed mood over time [39].
Additionally, there is a survey literature [26–33], not
reviewed here, documenting return to work rates and the
assessment of work-related functional abilities measured
using instruments such as the ‘Work Ability Index’ [79]
or the ‘Work Limitations Questionnaire’ [80] in patients
with, or treated for, cancer. A few qualitative studies [34,
35, 40] have described the value and meaning of paid
work in patients’ lives and barriers to re-joining the work-
force. However, the current review found little of patients’
own perceptions of the impact of cancer and its treatments
on these aspects of life measured using a comprehensive
PRO. The two validated multidimensional instruments
identified (IIRS, SDI) have single items asking about
impact on work amounting to nothing above that already
found in the frequently used, validated, HRQoL instru-
ments (EORCT-QLQ-C30 or FACT-G).
Two validated multidimensional PROs were identified, the
IIRS [74] and SDI [10], which capture a broad range of as-
pects of patients’ everyday lives albeit balanced with brevity.
The SDI is of particular relevance since it has been specifically
developed for the oncology setting with the aim of being used
as a tool to facilitate the integration of the assessment of social
well-being into routine care in a way similar to that advocated
for psychological well-being [76, 77]. Its purposes are to aid
detection and characterisation of social problems and to im-
prove communication between patients and healthcare profes-
sionals about this, leading to appropriate service responses,
including if necessary onward referral and ultimately better
care and enhanced well-being for patients. Other ways that it,
and similar instruments, could be used include for the research
and development of interventions to help patients manage
social impacts like financial burden or family caregiving re-
sponsibilities, or perhaps as part of survivorship care plans, as
well as for assessing any differential impacts of treatments
being compared in clinical trials.
Nevertheless, clearly insufficient data are being gatheredwith
patients to comprehensively understand their problems and
needs to enable supporting them living well with their disease,
including making decisions about ongoing treatment options.
Impacts on the social domain need to be consistently assessed
more comprehensively and this has implications for the current
HRQoL instruments commonly used. Options for the future
include using the SDI in tandem with the existing well-
validated quality of life measures and/or generating further as-
sessment modules (i.e. subscales) for the existing instruments.
Limitations
This review was intentionally restricted to identifying studies
that reported the use of PRO instruments dedicated solely to the
assessment of the financial situation, lifestyle, occupational cir-
cumstances, and roles and responsibilities with dependents
(looking after young offspring or elderly parents) of adult can-
cer patients living with advanced disease. In taking this ap-
proach, we acknowledge that we have not conducted a map-
ping and review process of existing social domain subscales of
either the general or the more specific health-related quality of
life instruments available to use in oncology and that such an
undertaking could reveal further useful validated measurement
items. One such tool absent from the current review is the
Patient-Reported Outcomes Measurement Information
System (PROMIS) [81], a product of the National Institutes
of Health (NIH) in the USA. This is because existing literature
on its social health domain measure (which covers companion-
ship, social isolation, social roles and activities and social
J Cancer Surviv
support) [82] is about its development and psychometrics,
meaning it either did not meet the search terms and/or inclusion
criteria or did meet an exclusion criterion. However, it is likely
to have significant presence in the future, and an awareness of it
is important. It has an item bank approach to its method of
development, has been evolved with patients and content ex-
perts and has undergone rigorous testing and validation con-
tinues to be ongoing. It has a scoring system to norm responses
to the general US population with free access and use.
Conclusions
There is a need and opportunity for further work, both in terms
of instrument use and development, to ensure that the social
areas of patients’ lives are comprehensively assessed. Our
tools must keep pace with changes happening in cancer treat-
ment outcomes so that salient social problems are anticipated
and/or ameliorated. The COST and SDI, two well-developed
and validated tools, could be used to supplement shortfalls in
the commonly employed HRQoL instruments. But, there is
also scope for developing additional subscales within the
existing modular systems to enhance them. In particular, at-
tention needs to be directed towards roles and responsibilities,
including work and patients with dependents.
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